Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.71 |
| ▸ | PYGL | P06737 | 9/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | PYGM | P11217 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7823632 | 0.84 | KDM4E (0.55) | PYGLPYGMALDH1A1MAPTTDP1 | |
| SCHEMBL3737969 | 0.82 | MEN1 (0.73) | MEN1KMT2ASMN1; SMN2GAAPKM | |
| SCHEMBL5753134 | 0.81 | MAPK1 (0.57) | MEN1KMT2ASMN1; SMN2PYGMALDH1A1 | |
| SCHEMBL2312527 | 0.81 | MEN1 (0.63) | MEN1KMT2APYGLSMN1; SMN2ALDH1A1 | |
| SCHEMBL5752469 | 0.81 | MAPT (0.54) | MEN1KMT2APYGLSMN1; SMN2GAA | |
| SCHEMBL17819637 | 0.80 | PYGL (0.54) | MEN1KMT2APYGLSMN1; SMN2PYGM | |
| SCHEMBL3737974 | 0.78 | MEN1 (0.69) | MEN1KMT2ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL4683934 | 0.78 | KMT2A (0.62) | MEN1KMT2ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL4683941 | 0.78 | KMT2A (0.62) | MEN1KMT2ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL4686928 | 0.78 | KMT2A (0.65) | MEN1KMT2ASMN1; SMN2GAAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110664816-A | SECA inhibitors and methods of making and using the same | 佐治亚州立大学研究基金会公司 | 2020-01-10 | — | — | CN | disclosed |
| US-20180179233-A1 | NEAR-IR GLUCOSE SENSORS | PROFUSA, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20150240283-A1 | Compound | Kingston Universty Higher Education Corporation (GB) | 2015-08-27 | — | — | US | disclosed |
| US-20150240283-A1 | Compound | Kingston Universty Higher Education Corporation (GB) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150240283-A1 | Compound | RPIA, STS, CLPP | MEN1 4222/4885KMT2A 911/4885PYGL 3218/4885 |
| US-20180179233-A1 | NEAR-IR GLUCOSE SENSORS | IRS1, INSR, SLC2A4 | MEN1 3439/4885KMT2A 3577/4885PYGL 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.